In the last trading session, 3.2 million Iterum Therapeutics plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 1.25. With the company’s per share price at $0.53 changed hands at $0.01 or 1.72% during last session, the market valuation stood at $102.86M. ITRM’s last price was a discount, traded about -464.15% off its 52-week high of $2.99. The share price had its 52-week low at $0.45, which suggests the last value was 15.09% up since then. When we look at Iterum Therapeutics plc’s average trading volume, we note the 10-day average is 2.76 million shares, with the 3-month average coming to 6.04 million.
Analysts gave the Iterum Therapeutics plc (ITRM) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended ITRM as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Iterum Therapeutics plc’s EPS for the current quarter is expected to be $0.12.
Iterum Therapeutics plc (NASDAQ:ITRM) trade information
Instantly ITRM was in green as seen at the end of in last trading. With action -0.91%, the performance over the past five days has been red. The jump to weekly highs of 0.5681 on Monday, 10/25/21 added 1.72% to the stock’s daily price. The company’s shares are showing year-to-date downside of -46.30%, with the 5-day performance at -0.91% in the red. However, in the 30-day time frame, Iterum Therapeutics plc (NASDAQ:ITRM) is -1.36% down. Looking at the short shares, we see there were 2.91 million shares sold at short interest cover period of 0.33 days.
The consensus price target for the stock as assigned by Wall Street analysts is $1.00, meaning bulls need an upside of 47.0% from its current market value. According to analyst projections, ITRM’s forecast low is $1.00 with $1.00 as the target high. To hit the forecast high, the stock’s price needs a -88.68% plunge from its current level, while the stock would need to soar -88.68% for it to hit the projected low.
Iterum Therapeutics plc (ITRM) estimates and forecasts
Data shows that the Iterum Therapeutics plc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -55.74% over the past 6 months, a 87.10% in annual growth rate that is considerably higher than the industry average of 17.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Iterum Therapeutics plc will rise 120.00%, while the growth in revenue is estimated to hit 81.50% for the next quarter.
The 2021 estimates are for Iterum Therapeutics plc earnings to increase by 69.50%.
Iterum Therapeutics plc is expected to release its next quarterly earnings report between August 04 and August 09.
Iterum Therapeutics plc (NASDAQ:ITRM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.59% of Iterum Therapeutics plc shares while 9.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 9.64%. There are 9.58% institutions holding the Iterum Therapeutics plc stock share, with Canaan Partners X LLC the top institutional holder. As of Mar 30, 2021, the company held 0.97% of the shares, roughly 1.73 million ITRM shares worth $2.44 million.
Frazier Management LLC holds the second largest percentage of outstanding shares, with 0.86% or 1.54 million shares worth $2.17 million as of Mar 30, 2021.
With 96173.0 shares estimated at $0.14 million under it, the former controlled 0.05% of total outstanding shares.